EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Novel RXR Agonist MSU-42011 Differentially Regulates Gene Expression in Mammary Tumors of MMTV-Neu Mice

Lyndsey A Reich iD, Ana S Leal, Edmund Ellsworth, Karen T Liby

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms24054298 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Lyndsey A Reich und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, College of Osteopathic Medicine, East Lansing, MI 48824, USA. Hauptthemen laut MEDLINE: Mammary Neoplasms, Animal, Tetrahydronaphthalenes. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Breast Cancer Research Foundation, MSU Targeted Support Grant for Technology Development, Targeted Support Grant for Technology Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Retinoid X receptor (RXR) agonists, which activate the RXR nuclear receptor, are effective in multiple preclinical cancer models for both treatment and prevention. While RXR is the direct target of these compounds, the downstream changes in gene expression differ between compounds. RNA sequencing was used to elucidate the effects of the novel RXRα agonist MSU-42011 on the transcriptome in mammary tumors of HER2+ mouse mammary tumor virus (MMTV)-Neu mice. For comparison, mammary tumors treated with the FDA approved RXR agonist bexarotene were also analyzed. Each treatment differentially regulated cancer-relevant gene categories, including focal adhesion, extracellular matrix, and immune pathways. The most prominent genes altered by RXR agonists positively correlate with survival in breast cancer patients. While MSU-42011 and bexarotene act on many common pathways, these experiments highlight the differences in gene expression between these two RXR agonists. MSU-42011 targets immune regulatory and biosynthetic pathways, while bexarotene acts on several proteoglycan and matrix metalloproteinase pathways. Exploration of these differential effects on gene transcription may lead to an increased understanding of the complex biology behind RXR agonists and how the activities of this diverse class of compounds can be utilized to treat cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mammary Neoplasms, AnimalTetrahydronaphthalenesAnimalsMiceBexaroteneGene ExpressionMammary Tumor Virus, MouseRetinoid X Receptors

Stichwörter der Autor:innen

RXR agonistbreast cancertranscriptomics

Substanzen

BexaroteneRetinoid X ReceptorsTetrahydronaphthalenes

Autor:innen und Institutionen

  • Department of Pharmacology and Toxicology, College of Osteopathic Medicine, East Lansing, MI 48824, USA.
  • Medicinal Chemistry Facility, Michigan State University, East Lansing, MI 48824, USA.
  • Department of Pharmacology and Toxicology, Michigan State University, B430 Life Science Building, 1355 Bogue Street, East Lansing, MI 48824, USA.

ORCID-Profile: Lyndsey A Reich

Förderung

  • Breast Cancer Research Foundation
  • MSU Targeted Support Grant for Technology Development
  • Targeted Support Grant for Technology Development

Zitieren

APA

Reich, L. A., Leal, A. S., Ellsworth, E., & Liby, K. T. (2023). The Novel RXR Agonist MSU-42011 Differentially Regulates Gene Expression in Mammary Tumors of MMTV-Neu Mice. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24054298

Vancouver

Reich LA, Leal AS, Ellsworth E, Liby KT. The Novel RXR Agonist MSU-42011 Differentially Regulates Gene Expression in Mammary Tumors of MMTV-Neu Mice. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24054298

BibTeX
@article{Reich2023,
  author = {Reich, Lyndsey A and Leal, Ana S and Ellsworth, Edmund and Liby, Karen T},
  title = {The Novel RXR Agonist MSU-42011 Differentially Regulates Gene Expression in Mammary Tumors of MMTV-Neu Mice},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms24054298}
}
Kostenlos starten →